Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06434909 · ClinicalTrials.gov registry record · Phase 2
CYTALUX™for the Intraoperative Imaging of Prostate Cancer
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT06434909 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 9 participants.
The verdict
NCT06434909, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.)
Interventions
- DRUG Cytalux™ (pafolacianine) for fluorescent imaging
- PROCEDURE Image Guided Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06434909
The ClinicalTrials.gov registry entry for NCT06434909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytalux™ (pafolacianine) for fluorescent imaging is the first listed.
NCT06434909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06434909 about?
NCT06434909 is a clinical study titled "CYTALUX™for the Intraoperative Imaging of Prostate Cancer". This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate canc...
What is the current status of trial NCT06434909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2024-09-19. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT06434909?
The interventions under investigation include: Cytalux™ (pafolacianine) for fluorescent imaging (DRUG), Image Guided Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT06434909?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.